Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Ciba-Geigy transfers marketing responsibility for the prescription nicotine transdermal patch from its Rx to its OTC sales force, effective Jan. 1, in anticipation of a switch to over-the-counter status. Ciba said its smoking cessation product is in clinical trials to support OTC marketing. Habitrol sales since its 1991 launch have totaled $450 mil. in the U.S., although Ciba noted that the nicotine replacement category has declined in recent years. In a similar move, Marion Merrell Dow transferred marketing responsibility for its prescription Nicorette gum to SmithKline Beecham's consumer products group last January ("The Tan Sheet" Aug. 23, 1993, p. 1). MMD markets an Rx patch as well. Also last January, McNeil Consumer acquired U.S. and Canadian marketing rights to the Nicotrol prescription patch from Warner-Lambert

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts